News
ACUT
0.258
NaN%
--
Weekly Report: what happened at ACUT last week (0601-0605)?
Weekly Report · 1d ago
Weekly Report: what happened at ACUT last week (0525-0529)?
Weekly Report · 06/01 09:26
Weekly Report: what happened at ACUT last week (0518-0522)?
Weekly Report · 05/25 09:28
Weekly Report: what happened at ACUT last week (0511-0515)?
Weekly Report · 05/18 09:27
AccuStem net loss widens 10% to $485,883 in Q1 FY26
PUBT · 05/15 20:10
Weekly Report: what happened at ACUT last week (0504-0508)?
Weekly Report · 05/11 09:26
Weekly Report: what happened at ACUT last week (0427-0501)?
Weekly Report · 05/04 09:25
Weekly Report: what happened at ACUT last week (0420-0424)?
Weekly Report · 04/27 09:26
Weekly Report: what happened at ACUT last week (0413-0417)?
Weekly Report · 04/20 09:25
Accustem FY25 net loss widens 16.68% to $1,756,096
PUBT · 04/14 20:33
Weekly Report: what happened at ACUT last week (0406-0410)?
Weekly Report · 04/13 09:26
Weekly Report: what happened at ACUT last week (0330-0403)?
Weekly Report · 04/06 09:26
Accustem Sciences delays filing annual report, expects 10-K within 15 days
Reuters · 04/01 00:57
Weekly Report: what happened at ACUT last week (0323-0327)?
Weekly Report · 03/30 09:26
Weekly Report: what happened at ACUT last week (0316-0320)?
Weekly Report · 03/23 09:25
Weekly Report: what happened at ACUT last week (0309-0313)?
Weekly Report · 03/16 09:25
Weekly Report: what happened at ACUT last week (0302-0306)?
Weekly Report · 03/09 09:25
Weekly Report: what happened at ACUT last week (0223-0227)?
Weekly Report · 03/02 09:25
Weekly Report: what happened at ACUT last week (0216-0220)?
Weekly Report · 02/23 09:25
Weekly Report: what happened at ACUT last week (0209-0213)?
Weekly Report · 02/16 09:25
More
Webull provides a variety of real-time ACUT stock news. You can receive the latest news about ACCUSTEM SCIENCES INC through multiple platforms. This information may help you make smarter investment decisions.
About ACUT
AccuStem Sciences, Inc. is a clinical-stage diagnostics company. It is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. It focuses on its proprietary genomic tests, MicroRNA Signature Classifier (MSC) for patients with lung nodules and StemPrintER for patients with early-stage breast cancer. The MSC test, a 24-micro-RNA (miRNA) assay designed to help determine whether lung nodules identified by low-dose computer tomography (LDCT) screening, are benign or malignant. StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. The assay is developed to measure the stemness of tumors, or how much a tumor behaves like stem cells, which could indicate how likely a cancer is to recur or be resistant to standard treatments, ultimately impacting how patients are managed by their multidisciplinary care team.